Pherin Pharmaceuticals: VistaGen acquires second Pherin nasal spray

VistaGen Therapeutics said that it has exercised an option to acquire an exclusive worldwide license for Pherin Pharmaceutical's PH10 intranasal steroid, which is in Phase 2 development for the treatment of major depressive disorder (MDD). According to the company, a Phase 2a study of PH10 conducted by MIchael Liebowitz of Columbia University demonstrated significant improvement [...]